Atopic Dermatitis Research Study

UC Health Office of Clinical Research   Cincinnati, OH   Full-time     Manufacturing / Production / Operations
Apply Now
Posted on March 30, 2021

Atopic Dermatitis Research Study

Do you have itching due to Atopic Dermatitis?

What The purpose of this clinical research study is to evaluate whether Nemolizumab, a new drug not approved by the FDA, can help reduce itching in people with Atopic Dermatitis. Who Individuals with moderate-to-severe atopic dermatitis. Pay Participants will be paid $108.00 per completed visit (up to $1,512.00 total if all study visits are completed)

Efficacy And Safety Of A Treatment For Eczema (Atopic Dermatitis)

  • Investigator: Alan Fleischer
  • Specialties: Dermatology, Skin Disease
  • Type of Study: Drug

This is a placebo-controlled study in adult and adolescent participants with moderate to severe atopic dermatitis. The study drug is an antibody that blocks a receptor involved with atopic dermatitis development and itchiness. Eligible participants will be randomly distributed to the experimental (drug) or placebo group in a ratio (2:1). Eligible participants will receive subcutaneous injections for 16-weeks. At week 16 visit participants will be evaluated as responders or non-responders. The responders will continue to the maintenance period of the study. The non-responders may be eligible to enroll into a long-term extension study.

Criteria:

Eligible Subjects Must Have Documented History Of Atopic Dermatitis For At Least 2 Years; Easi Score >16; Iga>3; Bsa Involvement >10%; Failure To Achieve Or Maintain Disease Remission; Agree To Apply Moisturizer During The Duration Of The Study; Willing To Comply With All Procedures, Including Recording Daily Diary.